Loading clinical trials...

Everolimus Modulation of Anti-tumor T CD4 Immune Responses | Clinical Trials | Clareo Health

TERMINATEDNA

Everolimus Modulation of Anti-tumor T CD4 Immune Responses

NCT02837757•Centre Hospitalier Universitaire de Besancon

Summary

Everolimus is an inhibitor of mammalian target of rapamycin, approved in patients with metastatic renal cell carcinoma. The objective of this study is to investigated the influence of everolimus immune modulation on antitumor efficacy .

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Performance status ECOG-WHO 0, 1 or 2
•Metastatic renal cancer
•Patient candidate to everolimus treatment
•signed written informed consent
•fertile women with adequate contraception during the study and until 8 weeks after stopping treatment

Exclusion Criteria

•Patients under chronic treatment with systemic corticoids or other immunosuppressive drugs (prednisone or prednisolone ≤ 10 mg/day is allowed)
•History of immune deficiency
•Hypersensitivity against rapamycin and derived
•Prior history of other malignancy except for: basal cell carcinoma of the skin, cervical intra-epithelial neoplasia and other cancer curatively treated with no evidence of disease for at least 5 years
•Active autoimmune diseases, HIV, hepatitis C or B virus
•Patients with any medical or psychiatric condition or disease,
•Patients under guardianship, curatorship or under the protection of justice.

Locations (3)

Centre Hospitalier Universitaire de Besançon

Besançon, France

Hôpital Nord Franche-Comté

Montbéliard, France

Hôpital Européen Georges Pompidou

Paris, France

Key Dates

Start Date

November 1, 2015

Primary Completion Date

December 18, 2019

Completion Date

December 18, 2019

Last Updated

May 16, 2022

Enrollment

ACTUAL participants

Conditions

Metastatic Renal Cancer

Interventions

Biological samples

OTHER

Lu-177 PSMA Treatment in Cell Renal Carcinoma

NCT06959433

Metastatic Renal Cancer

View study

NOT_YET_RECRUITINGPHASE2

A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma

NCT07123090

Metastatic Renal Cell CarcinomaMetastatic Renal Cancer+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 16, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Everolimus Modulation of Anti-tumor T CD4 Immune Responses

Inclusion Criteria

Exclusion Criteria

Lu-177 PSMA Treatment in Cell Renal Carcinoma

A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma

Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer